de Jonge, Maja J. A.
Steeghs, Neeltje
Lolkema, Martijn P.
Hotte, Sebastien J.
Hirte, Hal W.
van der Biessen, Diane A. J.
Abdul Razak, Albiruni R.
De Vos, Filip Y. F. L.
Verheijen, Remy B.
Schnell, David
Pronk, Linda C.
Jansen, Monique
Siu, Lillian L.
Funding for this research was provided by:
Boehringer Ingelheim
Article History
First Online: 11 February 2019
Compliance with ethical standards
:
: This trial was sponsored by Boehringer Ingelheim. This work was supported by Boehringer Ingelheim, Ingelheim am Rhein, Germany. BI 853520 is an asset of Boehringer Ingelheim. This article was published open access under a Springer Compact agreement with Dutch universities and Academy institutes.
: Hal W. Hirte reports receiving honoraria from AstraZeneca, Roche and Merck; Albiruni R. Abdul Razak reports paid expert testimony for, and grants from, Boehringer Ingelheim; and Filip Y.F.L. De Vos reports paid expert testimony for Bristol Myers Squibb, and grants from Novartis. Remy B. Verheijen is an employee of AstraZeneca; David Schnell and Linda C. Pronk are employees of Boehringer Ingelheim; and Monique Jansen was an employee of Boehringer Ingelheim at the time of study conduct and manuscript preparation. Lillian L. Siu reports institutional clinical trial funding for this study provided by Boehringer Ingelheim. Maja J.A. de Jonge, Neeltje Steeghs, Martijn P. Lolkema, Sebastien J. Hotte, and Diane A.J. van der Biessen declare that they have no conflicts of interest.